Vandetanib

Generic Name: Vandetanib

Brand Names: Caprelsa

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄BrFN_₄O_₂

CAS Number: 443913-73-3

Unique Ingredient Identifier: YO460OQ37K

Background: Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Indication: Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Associated Conditions: Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer

Clinical Trials

FDA Grants Full Approval to Selpercatinib for RET-Mutant Medullary Thyroid Cancer

8 months ago

• The FDA granted traditional approval to selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation in patients 2 years and older. • The approval was based on the LIBRETTO-531 trial, which demonstrated superior progression-free survival compared to cabozantinib or vandetanib. • Patients on selpercatinib reported less time with severe side effect bother than those on cabozantinib or vandetanib, improving overall tolerability. • Selpercatinib is now a preferred first-line treatment option for advanced RET-mutant medullary thyroid cancer, offering a targeted approach.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy